113 related articles for article (PubMed ID: 2470358)
1. Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease.
Müller B; Krais T; Stürzebecher S; Witt W; Schillinger E; Baldus B
Biomed Biochim Acta; 1988; 47(10-11):S40-4. PubMed ID: 2470358
[TBL] [Abstract][Full Text] [Related]
2. Iloprost in peripheral vascular disease--platelet function and clinical outcome.
Fitscha P; Tiso B; Sinzinger H
Prog Clin Biol Res; 1987; 242():463-8. PubMed ID: 2444993
[No Abstract] [Full Text] [Related]
3. Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog, in severe peripheral arterial disease (PAD).
Oberender H; Krais T; Schäfer M; Belcher G
Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():311-6. PubMed ID: 2473610
[No Abstract] [Full Text] [Related]
4. Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD).
Fitscha P; Tiso B; Krais T; Sinzinger H
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():450-4. PubMed ID: 2444079
[No Abstract] [Full Text] [Related]
5. [Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study].
Diehm C; Abri O; Baitsch G; Bechara G; Beck K; Breddin HK; Brock FE; Clevert HD; Corovic D; Marshall M
Dtsch Med Wochenschr; 1989 May; 114(20):783-8. PubMed ID: 2470569
[TBL] [Abstract][Full Text] [Related]
6. The influence of iloprost on blood rheology and tissue perfusion in patients with intermittent claudication.
Ciuffetti G; Sokola E; Lombardini R; Pasqualini L; Pirro M; Mannarino E
Kardiol Pol; 2003 Sep; 59(9):197-204. PubMed ID: 14618196
[TBL] [Abstract][Full Text] [Related]
7. Does prostacyclin analogue Iloprost change blood rheology? Results from a double blind trial with intravenous application in diabetics.
Ernst E; Marshall M; Matrai A
Vasa; 1988; 17(2):89-91. PubMed ID: 2457284
[No Abstract] [Full Text] [Related]
8. Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue.
Kaliman J; Fitscha P; Barth H; Sinzinger H
Prog Clin Biol Res; 1987; 242():469-77. PubMed ID: 3313421
[No Abstract] [Full Text] [Related]
9. Comparison of the thromboxane synthetase inhibitor dazoxiben and the prostacyclin mimetic iloprost in an animal model of acute ischaemia and reperfusion.
Thiemermann C; Schrör K
Biomed Biochim Acta; 1984; 43(8-9):S151-4. PubMed ID: 6083783
[TBL] [Abstract][Full Text] [Related]
10. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group.
Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148
[TBL] [Abstract][Full Text] [Related]
11. Temporary inhibition of platelet function with iloprost (ZK36374) preserves canine platelets during extracorporeal membrane oxygenation.
Cottrell ED; Kappa JR; Stenach N; Fisher CA; Tuszynski GP; Switalska HI; Addonizio VP
J Thorac Cardiovasc Surg; 1988 Oct; 96(4):535-41. PubMed ID: 2459560
[TBL] [Abstract][Full Text] [Related]
12. Possibilities for clinical use of prostacyclin in vascular disease.
Poredos P
Pflugers Arch; 2000; 440(5 Suppl):R137-8. PubMed ID: 11005643
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effectiveness of prostaglandins (PGs) in peripheral vascular disease (PVD).
Linet OI; Mohberg NR
Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():307-10. PubMed ID: 2473609
[No Abstract] [Full Text] [Related]
14. Vascular prostacyclin release and metabolic derangement in diabetes.
Harrison HE; Johnson M
Horm Metab Res Suppl; 1981; 11():43-9. PubMed ID: 7033096
[TBL] [Abstract][Full Text] [Related]
15. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease.
Cronenwett JL; Zelenock GB; Whitehouse WM; Lindenauer SM; Graham LM; Stanley JC
Surgery; 1986 Aug; 100(2):369-75. PubMed ID: 3526609
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease.
Sinzinger H; Virgolini I; O'Grady J
Prog Clin Biol Res; 1989; 301():85-96. PubMed ID: 2477859
[No Abstract] [Full Text] [Related]
17. [Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative].
Brock FE; Abri O; Baitsch G; Bechara G; Beck K; Corovic D; Diehm C; Marshall M; Rahmel B; Scheffler P
Schweiz Med Wochenschr; 1990 Oct; 120(40):1477-82. PubMed ID: 1699272
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, crossover comparison of iloprost with dextran in patients with peripheral arterial occlusive disease.
Ylitalo P; Kaukinen S; Reinikainen P; Salenius JP; Vapaatalo H
Int J Clin Pharmacol Ther Toxicol; 1990 May; 28(5):197-204. PubMed ID: 1694831
[TBL] [Abstract][Full Text] [Related]
19. In vivo modulation of platelet deposition on human atherosclerotic lesions by various antiaggregatory prostaglandins.
Fitscha P; Kaliman J; O'Grady J; Sinzinger H
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):443-6. PubMed ID: 2465949
[TBL] [Abstract][Full Text] [Related]
20. Platelet responses observed during and after infusions of the prostacyclin analog ZK 36 374.
Yardumian DA; Mackie IJ; Bull H; Machin SJ
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():359-62. PubMed ID: 2408446
[No Abstract] [Full Text] [Related]
[Next] [New Search]
